Taken together, our study showed a commonly used chemotherapeutic CY was able to enhance the anti-tumor effect of TGFβ inhibitor, resulting in the potent inhibition in the development of 4T1 mouse mammary carcinoma. This evidence concerns the gene TGFB1 and breast carcinoma.